Bremer Bank National Association Buys New Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Bremer Bank National Association purchased a new stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 63,833 shares of the company's stock, valued at approximately $4,990,000.

A number of other institutional investors also recently modified their holdings of the business. Mercer Global Advisors Inc. ADV increased its position in GE HealthCare Technologies by 15.7% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 24,326 shares of the company's stock worth $1,931,000 after purchasing an additional 3,303 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its holdings in shares of GE HealthCare Technologies by 7.7% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 2,405 shares of the company's stock worth $187,000 after buying an additional 171 shares in the last quarter. Public Employees Retirement Association of Colorado lifted its stake in shares of GE HealthCare Technologies by 0.7% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 58,894 shares of the company's stock valued at $4,589,000 after acquiring an additional 408 shares during the last quarter. AE Wealth Management LLC boosted its holdings in shares of GE HealthCare Technologies by 206.3% during the 2nd quarter. AE Wealth Management LLC now owns 17,725 shares of the company's stock valued at $1,381,000 after acquiring an additional 11,938 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ grew its position in GE HealthCare Technologies by 7.7% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 89,251 shares of the company's stock worth $6,954,000 after acquiring an additional 6,400 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.

GE HealthCare Technologies Trading Down 0.3 %

Shares of GE HealthCare Technologies stock traded down $0.26 on Monday, reaching $84.74. 2,855,039 shares of the company's stock were exchanged, compared to its average volume of 2,724,028. The company has a market capitalization of $38.72 billion, a P/E ratio of 23.28, a price-to-earnings-growth ratio of 2.80 and a beta of 1.11. GE HealthCare Technologies Inc. has a 52 week low of $71.31 and a 52 week high of $94.55. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.98 and a current ratio of 1.23. The firm's 50-day moving average is $81.97 and its two-hundred day moving average is $84.48.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.08. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The business had revenue of $4.86 billion for the quarter, compared to analyst estimates of $4.87 billion. During the same period in the prior year, the firm earned $0.99 earnings per share. GE HealthCare Technologies's revenue was up .9% on a year-over-year basis. Sell-side analysts predict that GE HealthCare Technologies Inc. will post 4.3 EPS for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Tuesday, January 14th will be paid a dividend of $0.035 per share. This is an increase from GE HealthCare Technologies's previous quarterly dividend of $0.03. This represents a $0.14 dividend on an annualized basis and a yield of 0.17%. The ex-dividend date of this dividend is Tuesday, January 14th. GE HealthCare Technologies's dividend payout ratio is 3.30%.

Analyst Ratings Changes

Several research firms have commented on GEHC. Evercore ISI increased their target price on GE HealthCare Technologies from $98.00 to $102.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. Wells Fargo & Company lifted their target price on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an "overweight" rating in a research report on Thursday, October 31st. Jefferies Financial Group raised shares of GE HealthCare Technologies from a "hold" rating to a "buy" rating and boosted their target price for the stock from $95.00 to $103.00 in a report on Wednesday, January 8th. UBS Group lowered shares of GE HealthCare Technologies from a "neutral" rating to a "sell" rating and cut their price target for the stock from $84.00 to $74.00 in a report on Thursday, September 26th. Finally, Stifel Nicolaus increased their price objective on GE HealthCare Technologies from $100.00 to $102.00 and gave the company a "buy" rating in a report on Monday, September 30th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $96.00.

Insiders Place Their Bets

In other GE HealthCare Technologies news, CEO Roland Rott sold 3,577 shares of the business's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the sale, the chief executive officer now owns 24,298 shares in the company, valued at approximately $2,101,291.04. The trade was a 12.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.27% of the company's stock.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.